Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03134352 | Study to Evaluate the Efficacy and Safety of ZL-3101 in Subjects With Subacute Eczema | PHASE2 | COMPLETED | 290 | — | — | Apr 26, 2017 | Sep 10, 2018 | Jan 24, 2019 | 6 | China |
To evaluate efficacy of Fugan ointment applied to involved skin of subjects with mild to moderate subacute eczema
| Arm | Type | Description |
|---|---|---|
| ZL-3101(Fugan) bid group | EXPERIMENTAL | Fugan AM + Fugan PM |
| ZL-3101(Fugan) qd group | EXPERIMENTAL | Fugan AM + Placebo PM |
| placebo group | PLACEBO_COMPARATOR | Placebo AM + Placebo PM |
| Name | Type | Description |
|---|---|---|
| ZL-3101 | DRUG | A brown ointment, 10g/tube, 0.4g herb/g ointment, Topical |
| Placebo | DRUG | A brown ointment, 10g/tube, 0.02 g herb/g ointment (5% of Fugan active ointment), Topical |
Inclusion Criteria: 1. Male or female subjects between 18 and 65 years of age inclusive, at the time of signing the informed consent; from outpatient clinic; 2. Subjects with a diagnosis of subacute eczema (Zhao 2001). Subacute eczema is often developed from improperly treated acute eczema or a few...